Visceral leishmaniasis and HIV in Tigray, Ethiopia
|
|
- Dominick Matthews
- 5 years ago
- Views:
Transcription
1 Tropical Medicine and International Health volume 8 no 8 pp august 2003 Visceral leishmaniasis and HIV in Tigray, Ethiopia Suzi Lyons 1, Hans Veeken 2 and Jean Long 3 1 Department of Public Health and Epidemiology, UCD, National University of Ireland, Dublin, Ireland 2 Medical Department, Médecins Sans Frontières, Amsterdam, The Netherlands 3 Department of Community Health and General Practice, Trinity Centre for Health Sciences, Tallaght, Ireland Summary objectives To identify characteristics that increased the risk of mortality in Ethiopian visceral leishmaniasis patients in a treatment programme managed by Médecins sans Frontières, in Tigray, Northern Ethiopia. methods Retrospective review of a cohort of 791 patients treated for visceral leishmaniasis. results The cohort displayed all the classical signs and symptoms of the disease. The case fatality rate was 18.5% (146) (95% CI: %). Logistic regression showed that individuals who experienced at least one episode of vomiting or haemorrhage were more likely to die than those who did not. A subcohort of individuals who tested human immunodeficiency virus (HIV)-positive were more than four times more likely to die than those who tested HIV-negative (OR 4.5, 95% CI: ). conclusion This study identifies characteristics associated with death in this population and highlights the devastating effect of co-infection with visceral leishmaniasis and HIV in the African context. keywords visceral leishmaniasis, HIV co-infection, mortality, Africa, Ethiopia Introduction Visceral leishmaniasis is a systemic parasitic illness, transmitted primarily by the sandfly from animal or human reservoirs (WHO 1990; Bryceson 1996). Untreated, the disease is usually fatal, but with appropriate treatment the case fatality rate drops to 10% or less (Bryceson 1996; Veeken et al. 2000). Visceral leishmaniasis is endemic in Ethiopia, with a patchy distribution in the southern and north-western lowlands (Maru 1979; WHO 1996). The causative parasite is Leishmania donovani, but the definitive reservoir remains unknown, although anthroponetic transmission has been implicated (WHO 1996). Tigray Province, the endemic region in the north west of Ethiopia, has historically reported only sporadic cases. Since 1970 the number of cases in the region has increased, which appears to correspond to an extensive programme of agricultural development with its annual influx of migrant workers (Mengesha & Abuhoy 1978; Maru 1979; Berhe et al. 2001). In response to this increase in cases, Médecins sans Frontières (MSF) opened a visceral leishmaniasis treatment centre in the region in Treatment is provided free of charge for all. Proximity to the frontline of the conflict between Ethiopia and Eritrea meant the site had to be moved twice for security reasons. Human immunodeficiency virus (HIV) is a major public health issue in Ethiopia and in 2002 it was estimated that 6.4% of adults were HIV-positive (UNAIDS et al. 2002). The influx of a high risk group, migrant workers, into Tigray makes a prevalence of HIV similar to or higher than the national level likely. Over the last decade visceral leishmaniasis has emerged as a major opportunistic infection associated with HIV in at least 28 countries, mainly in Europe (where L. infantum is the causative organism) (WHO & UNAIDS 1998; Desjeux 1999; Pintado & Lópéz-Vélez 2001). Research in Europe has found that individuals co-infected can present with vague and atypical symptoms of visceral leishmaniasis; absence of hepatosplenomegaly, non-specific gastrointestinal problems, with parasites often found outside the reticulo-endothelial system and negative serology (Davidson 1997; Desjeux 1999; Pintado et al. 2001). Co-infected patients have a much poorer prognosis, with up to 80% relapsing, and a reduced life-expectancy (WHO & UN- AIDS 1998; Desjeux 1999). To date there have been 271 reported cases of co-infection of HIV and visceral leishmaniasis in Ethiopia (Wolday et al. 2001). However, there is very little information on co-infection regarding estimation of true numbers, clinical presentation or outcome in Africa, where the causative organism is L. donovani (WHO & UNAIDS 1998; Wolday et al. 2001). This study documents the outcomes of a large cohort of individuals treated for visceral leishmaniasis, identifies factors that predict mortality and describes the clinical ª 2003 Blackwell Publishing Ltd 733
2 picture of visceral leishmaniasis in HIV co-infected patients. Material and methods The study was a retrospective review of treatment charts from patients admitted from 1 December 1998 to 1 May Diagnosis of visceral leishmaniasis was made on clinical presentation (case definition: fever for more than two weeks, with splenomegaly and/or wasting) (WHO 1990; Veeken 1998) and was confirmed by either (i) positive serology using direct agglutination test (DAT) titre 1:6 400 or by (ii) demonstration of parasites from spleen or lymph node aspiration. Individuals previously treated for visceral leishmaniasis were excluded from the study. The outcome of interest was death during treatment. Patients who completed and survived the full treatment programme (of 30 injections stibogluconate 20 mg/kg per day) and were discharged with recorded clinical improvement (with or without test of cure, i.e. clearance of parasites confirmed by splenic or lymphatic aspiration) were considered cured. Follow-up at six months to establish relapse was not undertaken in this study. HIV testing was performed during two distinct periods in the study. From December 1998 to April 1999 two rapid tests were used (Capillus and HIV spot) for all patients and those who had two positive results were considered HIV-positive. During this period a comparative drug trial was implemented at the treatment site and HIV tests were readily available. From October 1999 to May 2000 testing re-started, but due to scarcity of HIV tests, only one rapid test (either Capillus and HIV spot) was used for individuals fitting the WHO acquired immunodeficiency syndrome (AIDS) definition (WHO & UNAIDS 1998). Those with a positive test result were considered HIV-positive. HIV testing was voluntary, and pre- and post-test counselling was provided. Laboratory confirmation of visceral leishmaniasis, HIV or other conditions was not always available due to proximity to the frontline with Eritrea, inconsistency of supplies, inaccessibility during the rainy season and lack of electricity. After pilot testing, 41 variables were collected from the charts, comprising data on demographics, clinical presentation on admission, laboratory tests, symptoms, co-morbidity and outcome. Only patient numbers were recorded so no individual can be identified from the study. Statistical analysis was carried out using JMP statistical package (SAS Institute 2000). Pearson Chi-square test, Fisher s exact test and crude odds ratios were used to compare proportions in independent groups of categorical data. Multiple logistic regression models were developed to determine which variables best predicted mortality. Exact 95% confidence intervals were calculated for proportions of binomial variables and for adjusted odds ratios. Denominators vary for each variable because not all sections of the charts were completed. The study was approved by Trinity College Public Health Research Ethics Committee. Results Between 1 December 1998 and 1 May 2000, 839 people were admitted to the programme and all had a documented outcome (i.e. survived/cured, died, defaulted or transferred). Of these 839, 48 were excluded from the study: 14 relapsed cases who had been treated previously, six cases with post-visceral leishmaniasis dermal leishmaniasis, 21 defaulters and seven transfers. Therefore 791 individuals with their first diagnosis of visceral leishmaniasis were included in the study analysis, of whom 645 were cured and 146 died. Three hundred and seventy-eight (47.8%) patients were diagnosed with a positive aspirate and 321 (40.6%) with positive serology. The remaining 92 (11.6%) individuals had either borderline/negative results in serology or aspirates (53) or no diagnostic test (39) and were all treated based on clinical signs and symptoms. The median age of the 791 cases of visceral leishmaniasis was 25 years (10 months to 77 years). More than threequarters of the cohort were aged between 15 and 45 years. The male to female ratio was 11:1; females were younger than males, with 42% of the females (27/64) younger than 15 compared to 9% of the males (68/722, P < 0.001). Children under the age of 15 had a lower mortality rate (3/95, 3%, 95% CI: 0.7 9%) than those aged 15 and over (142/692, 21%, 95% CI: %). There was no significant difference in mortality between those who had been diagnosed by laboratory tests (DAT or aspirate) and those treated on clinical grounds only (v 2 ¼ 1.0, d.f. ¼ 1, P ¼ 0.3). The cohort experienced the classical signs and symptoms associated with visceral leishmaniasis (Table 1). The overall death rate was 18.5% (95% CI: %). Of the 213 individuals tested for HIV antibodies, 49 (23%) were HIV (antibody) positive. One hundred and twenty-seven of the 213 tested individuals had two tests, with 24 testing positive. Eighty-six of the 213 tested for HIV underwent only one test (fitting the WHO AIDS definition), and 25 of them tested positive. The median age (range) of this group was 29 (18 55), all were over the age of 18 years and 45 (92%) were male. Of those who tested positive for HIV, three-quarters had one or more episodes of diarrhoea compared to half of those who tested negative for HIV antibodies (v 2 ¼ 9.5, d.f. ¼ 1, 734 ª 2003 Blackwell Publishing Ltd
3 Table 1 Signs and symptoms of Ethiopian visceral leishmaniasis patients (n ¼ 791) Signs and symptoms % No. diagnosed/ denominator Splemomegaly /754 Fever /728 Cough /730 Diarrhoea /737 Hepatomegaly /645 Vomiting /733 Haemorrhage /732 Oedema /734 Carried by stretcher* 13 91/701 BMI < /390 * Proxy for severe debilitation. Adults aged over 18, with no recorded oedema. P ¼ 0.002). There was no significant difference in mortality between those who had two tests (14, 10%) and those who had one test (10, 12.7%), (v 2 ¼ 0.3, d.f. ¼ 1, P ¼ 0.6). Of the 41 variables recorded, bivariate analysis identified 11 variables significantly associated with death (Table 2). In order to identify independent patient characteristics or risk factors that predicted mortality, logistic regression models were constructed to control for confounding and describe statistical interaction. Gender and the variables that were significant using bivariate analysis were entered in the models and only statistically significant variables were retained in the final models. Two separate models were created: model A excludes all those tested for HIV and model B includes only those tested for HIV. Model A (Table 3) shows that individuals admitted on a stretcher were 11 times more likely to die during treatment for visceral leishmaniasis than those who walked unaided or with the support of a stick. Individuals with a body mass index (BMI) of less than 16 were four times more likely to die than those with a BMI of 16 or more. Those who vomited one or more times during treatment were more than three times more likely die than those who did not vomit, while those who had a recorded haemorrhage during treatment were also more than three times more likely to die than those who did not. Individuals who experienced at least one episode of diarrhoea were more than twice as likely to die than those who did not have diarrhoea. In model B (Table 4), logistic regression was carried out on the subcohort of individuals who were tested for HIV. Three variables remained significant in this model: vomiting and haemorrhage, and, the most important predictor of death during treatment for visceral leishmaniasis, testing positive for HIV antibodies. HIV-infected people were more than four times more likely to die than those who tested negative for HIV. Discussion The study population displayed the classical signs and symptoms of visceral leishmaniasis, such as fever, cough and splenomegaly (Maru 1979; WHO 1990; Bryceson 1996). The death rate (18.5%, 95% CI: %) was higher than the expected 10% or less (WHO 1990; Bryceson 1996). It compares unfavourably to the death rates in other MSF treatment programmes, 5.7% in North Sudan and 11% in South Sudan, which were observed in severely debilitated patients (Seaman et al. 1996; Veeken et al. 2000). Although worldwide, more males than females are infected with visceral leishmaniasis (WHO 1990), the very high male to female ratio found in this study, 11:1, reflects the high numbers of single males who make up the migrant worker population in the Tigray region and who are at risk of contracting visceral leishmaniasis. The primary outcome of interest in the study was mortality during treatment for visceral leishmaniasis. Splenic aspirations to prove cure, at discharge, were not routinely done, consequently discharge was based on clinical improvement (feeling of well-being, absence of fever, weight gain) (Berhe et al. 2001). Follow-up of individuals six months after discharge is recommended to monitor episodes of relapse, but was beyond the scope of this study. The retrospective nature of the study meant it was limited to the information already recorded, information that had been originally collected to diagnose and treat cases rather than for research purposes, and values were missing for all of the variables. This limited the scope of the study to explore in more detail the predictors of death. The inaccessibility of the project site, because of conflict and weather conditions, meant that routine laboratory confirmation of visceral leishmaniasis, HIV and other conditions was not always possible due to lack of equipment and materials. Diagnosis of visceral leishmaniasis on clinical presentation was made for 92 (11.6%) cases. The proportion of cases who died was similar among those who had a laboratory test to confirm their diagnoses to those who were diagnosed using clinical criteria. HIV status was assessed for 213 individuals, in some cases based on the results of one rapid test. These tests have a sensitivity 98.8% or above and were used following WHO guidelines for surveillance. The individuals selected for HIV testing based on the WHO AIDS definition (WHO & UNAIDS 1998) and who subsequently had one rapid test were possibly at a more advanced stage of HIV illness, ª 2003 Blackwell Publishing Ltd 735
4 Characteristic Cured n (%) Died n (%) Crude odd ratios (CI) Age group (n) n ¼ 642 n ¼ years (95) 92 (96.8) 3 (3.2) years (659) 529 (80.3) 130 (19.7) 7.5 ( ) >45 years (33) 21 (63.6) 12 (36.4) 17.5 ( ) Gender (n) n ¼ 640 n ¼ 146 Male (722) 585 (81.0) 137 (19.0) 1 Female (64) 55 (85.9) 9 (14.1) 1.4 ( ) Mobility on admission (n) n ¼ 572 n ¼ 129 Walking (413) 367 (88.9) 46 (11.1) 1 Supported by a stick (197) 154 (78.2) 43 (21.8) 2.2 ( ) Carried by stretcher (91) 51 (56.0) 40 (44.0) 6.3 ( ) Duration of illness before admission (n) n ¼ 580 n ¼ weeks (474) 407 (85.9) 67 (14.1) weeks (183) 126 (68.9) 37 (20.2) 1.8 ( ) weeks (51) 35 (68.6) 16 (31.4) 2.7 ( ) weeks (16) 12 (75.0) 4 (25.0) 1.4 ( ) BMI (n) n ¼ 314 n ¼ (274) 234 (85.4) 40 (14.6) 1 <16 (116) 80 (69.0) 36 (31.0) 2.6 ( ) Haemorrhage (n) n ¼ 599 n ¼ 133 At least one recorded episode (161) 100 (62.1) 61 (45.9) 1 No recorded episodes (571) 499 (87.4) 72 (12.6) 4.2 ( ) Diarrhoea (n) At least one recorded episode (381) 285 (74.8) 96 (25.2) 1 No recorded episodes (356) 319 (89.6) 37 (10.4) 2.9 ( ) Vomiting (n) n ¼ 601 n ¼ 132 At least one recorded episode (206) 147 (71.4) 59 (28.6) 1 No recorded episodes (527) 454 (86.1) 73 (13.9) 2.5 ( ) Site of oedema (n) n ¼ 599 n ¼ 135 None recorded (617) 506 (82.0) 111 (18.0) 1 Ascites (25) 12 (48.0) 13 (52.0) 4.9 ( ) Other * (92) 81 (88.0) 11 (12.0) 0.6 ( ) Neurological complications (n) n ¼ 599 n ¼ 136 No complications recorded (723) 596 (82.4) 127 (17.6) 1 One or more complication (12) 3 (25.0) 9 (75.0) 14.1 ( ) Jaundice (n) n ¼ 599 n ¼ 136 No jaundice recorded (730) 599 (82.1) 131 (17.9) 1 Jaundice (6) 1 (16.7) 5 (83.3) 22.9 ( ) HIV status (n) n ¼ 189 n ¼ 24 Negative (164) 153 (93.3) 11 (6.7) 1 Positive (49) 36 (73.5) 13 (26.5) 5.0 ( ) Table 2 Characteristics associated with death from visceral leishmaniasis in Ethiopian patients despite treatment * Other sites of oedema: feet, lower limbs, scrotum, face. Coma, convulsions, psychiatric disturbance or mono-neuropathy. because they had been identified based on physical signs and symptoms rather than a guideline to test all newly admitted cases. Routine testing of all new cases was the policy only during the comparative drug trial period. Therefore, those selected for testing using the WHO definition were, in theory, more likely to die and therefore this analysis could overestimate the magnitude of the effect of HIV. The use of two regimes limits the generalisability of the results. But there was no significant difference in mortality between those who had two tests and those who had one test. There was no significant difference in mortality rates with regard to the comparative drug trial which ran for a period in the treatment programme (Veeken et al. 2000). The clinical presentation of visceral leishmaniasis can be largely indistinguishable from AIDS-related illnesses, for example, weight loss, fever and splenomegaly (WHO & UNAIDS 1998; Desjeux 1999). Also, very little is known as yet about the symptoms of visceral leishmaniasis and HIV co-infection in African populations (WHO & UNAIDS 736 ª 2003 Blackwell Publishing Ltd
5 Table 3 Model A: logistic regression model* to identify the characteristics that predict death from visceral leishmaniasis despite appropriate treatment in the subcohort not tested for HIV Total no. Died no. (%) Adjusted odds ratio P-value Mobility Walked/stick (16.5) 1 Carried by stretcher (55.0) 11.1 ( ) BMI > (18.8) 1 < (38.3) 3.8 ( ) Haemorrhaged at least once No (14.3) 1 Yes (50.0) 3.1 ( ) Vomited at least once No (16.1) 1 Yes (34.1) 3.5 ( ) Diarrhoea at least once No (12.2) 1 Yes (29.5) 2.6 ( ) 0.02 Whole model v 2 ¼ 70.62, R 2 ¼ 0.28, P ¼ < * Initial model also included gender, duration of illness before admission, spleen and liver size on admission, oedema, neurological complications and clinical signs of HIV. Table 4 Model B: logistic regression model* to identify the characteristics that predict death from visceral leishmaniasis in the subcohort of 213 tested for HIV Of n ¼ 213 Of deaths n ¼ 24 No. No. (%) Adjusted odds ratio (95% CI) P-value HIV status Negative (6.7) 1 Positive (26.5) 4.5 ( ) Haemorrhaged at least once No (8.0) 1 Yes (17.4) 2.7 ( ) 0.04 Vomited at least once No (7.7) 1 Yes (18.3) 2.6 ( ) 0.04 Whole model v 2 ¼ 20.77, R 2 ¼ 0.14, P ¼ < * Initial model also included gender, mobility on admission, duration of illness before admission, BMI, spleen and liver size on admission, diarrhoea, oedema, neurological complications and clinical signs of HIV. 1998; Wolday et al. 2001). There was no evidence of atypical presentation of visceral leishmaniasis and HIV co-infection in this study population. Apart from age, the only statistically significant clinical difference between HIV-negative and HIV-positive visceral leishmaniasis patients was diarrhoea (P ¼ 0.005). Multiple regression was carried out on two separate subcohorts, those not tested for HIV antibodies (model A) and those tested (model B). In model A, five independent factors that predicted death among those treated for visceral leishmaniasis were identified. These were: admitted by stretcher (proxy for debilitation), BMI less than 16 (proxy for wasting), haemorrhage, vomiting and diarrhoea. In model B, the subcohort of individuals who were tested for HIV antibodies, vomiting and haemorrhage were again identified as independent risk factors that predicted death among those treated for visceral leishmaniasis. In addition, in this group HIV-positive status was the most important predictor of death among those treated for visceral leishmaniasis. Haemorrhage is frequently associated with visceral leishmaniasis both as a symptom and risk factor for death (WHO 1990; Bryceson 1996), but this is the first study to show it as an independent predictor of death. However due ª 2003 Blackwell Publishing Ltd 737
6 to lack of data, it could not be established if site of bleeding or severity of bleeding were factors for mortality. Using bivariate analysis, a study in South Sudan had already found an association between vomiting and increased likelihood of death (Seaman et al. 1996) while we found that vomiting at least once during treatment was an independent risk factor for death. The difference in the other significant variables between the two models is intriguing. Seaman s study in South Sudan found that a BMI of less than 12 was an independent predictor of death (Seaman et al. 1996). Being carried by a stretcher is obviously an indicator of severe illness, as more than half (55%) of these individuals died. The symptom diarrhoea was examined for interaction with other variables and none was observed. Using bivariate analysis, experiencing one or more episodes of diarrhoea was more common among HIV-positive than HIV-negative individuals. One must also consider the independent effect of HIV co-infection on the population. Although model B has a smaller number of subjects than model A, it showed that those who were HIV-positive were also five times more likely to die than those who were not. The effect on mortality of undiagnosed HIV in the untested group (model A) cannot be assessed and this is another limitation of the study. Although in this group debilitation, wasting and diarrhoea were independent risk factors for death during treatment, they are also possible signs and symptoms of the opportunistic conditions associated with HIV/AIDS. What is certain is that with the spread of HIV infection to rural areas and the large-scale migrant movements, these two diseases will continue to collide in visceral leishmaniasis endemic areas. Currently as there is no affordable treatment available for HIV/AIDS in the African context, preventive measures must be taken to reduce the incidence of both HIV and visceral leishmaniasis. Community education on both visceral leishmaniasis and HIV prevention, intensive treatment of sexually transmitted diseases, vector control, and use of impregnated bed nets to reduce transmission are suggested interventions to halt the spread of these infections (WHO & UNAIDS 1998; Desjeux 1999). Other measures to be considered for those with visceral leishmaniasis are active case-finding, rigorous follow up of treated cases, treatment of relapsed cases (who may be a reservoir for visceral leishmaniasis) and routine testing for HIV in all visceral leishmaniasis patients infections (WHO & UNAIDS 1998; Desjeux 1999; Wolday et al. 2001). Finally, research to identify the unknown reservoir and new treatment protocols should also be actively pursued, in conjunction with improved epidemiological surveillance in affected countries. Acknowledgements We thank the staff at MSF for their support and assistance, in particular Dr Michael Marlett and Dr Yousef Melaku. Thanks to the staff at the Department of Community Health and General Practice, TCD also, for their support during this project. References Berhe N, Hailu A, Abraham Y et al. (2001) Inter-current and nosocomial infections among visceral leishmaniasis patients in Ethiopia: an observational study. Acta Tropica 80, Bryceson A (1996) Leishmaniasis. In: Manson s Tropical Diseases. 12th (edn.) (ed. G Cook) Saunders, London, pp Davidson R (1997) Aids and leishmaniasis. Genitourinary Medicine 73, Desjeux P (1999) Global control and Leishmania HIV co-infection. Clinics in Dermatology 17, Maru M (1979) Clinical and laboratory features and treatment of visceral leishmaniasis in hospitalized patients in northwestern Ethiopia. American Journal of Tropical Medicine 28, Mengesha B & Abuhoy M (1978) Kala-azar among labour migrants in Metema-Humera region of Ethiopia. Tropical and Geographical Medicine 30, Pintado V & Lópéz-Vélez R (2001) HIV-associated visceral leishmaniasis. Clinical Microbiology and Infectious Diseases 7, Pintado V, Martín-Rabadán R, Rivera M et al. (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-infected patients. Medicine (Baltimore) 80, SAS Institute (2000) JMP Statistical Discovery Software. Duxbury Press, Cary. Seaman J, Mercer A, Sondorp E & Herwaldt B (1996) Epidemic visceral leishmaniasis in Southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Annals of Internal Medicine 124, UNAIDS, UNICEF & World Health Organization (2002) Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Diseases: Ethiopia. WHO, Geneva. Veeken H (1998) Manual of the Treatment of Visceral Leishmanasis. Medecins Sans Frontieres, Amsterdam. Veeken H, Ritmeijer K, Seaman J & Davidson R (2000) A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Tropical Medicine and International Health 5, Wolday D, Berhe N, Auffo H, Desjeux P & Britton S (2001) Emerging Leishmania/HIV co-infection in Africa. Medical Mircobiology and Immunology 150, WHO (1990) Control of the Leishmaniases. WHO, Geneva. WHO (1996) Manual on Visceral Leishmania Control. WHO, Geneva. WHO & UNAIDS (1998) Leishmania and HIV in Gridlock. WHO, Geneva. 738 ª 2003 Blackwell Publishing Ltd
7 Authors Suzi Lyons, Department of Public Health and Epidemiology, University College Dublin, Earlsfort Terrace, National University of Ireland, Dublin 2, Ireland. Tel.: ; Fax: ; suzanne.lyons@ucd.ie (corresponding author). Dr Hans Veeken, Medical Department, Médecins Sans Frontières, Max Euweplein 40, 1001 EA, Amsterdam, The Netherlands. hansveeken@chello.nl Dr Jean Long, Department of Community Health and General Practice, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children s Hospital, Tallaght, Dublin 24, Ireland. Tel.: ; jelong@tcd.ie ª 2003 Blackwell Publishing Ltd 739
A Comparison of Miltefosine and Sodium. Ritmeijer, K; Dejenie, A; Assefa, Y; Hundie, T B; Mesure, J; Boots, G; den Boer, M; Davidson, R N
MSF Field Research A Comparison of and Sodium Stibogluconate for Treatment of Visceral Leishmaniasis in an Ethiopian Population with High Prevalence of HIV Infection. Authors Citation Ritmeijer, K; Dejenie,
More informationWorld Health Organization Department of Communicable Disease Surveillance and Response
WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases World Health Organization Department of Communicable Disease Surveillance and Response This document has been downloaded from the
More informationAuthors Chappuis, François; Alirol, Emilie; Worku, Dagemlidet T; Mueller, Yolanda; Ritmeijer, Koert
MSF Field Research High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B Item type Article
More informationMueller, Y; Mbulamberi, Dawson B; Odermatt, Peter; Hoffmann, Axel; Loutan, Louis; Chappuis, François
MSF Field Research Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Authors Citation DOI Journal Rights Mueller, Y; Mbulamberi, Dawson B; Odermatt, Peter; Hoffmann,
More informationter Horst, Rachel; Tefera, Tewodros; Assefa, Gessesse; Ebrahim, Abdurazik Z; Davidson, Robert N; Ritmeijer, Koert
MSF Field Research Field evaluation of rk39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia Item
More informationAuthors Babiker, Z O E; Davidson, R N N; Mazinda, C; Kipngetich, S; Ritmeijer, K
MSF Field Research Utility of Lymph Node Aspiration in the Diagnosis of Visceral Leishmaniasis in Sudan. Authors Babiker, Z O E; Davidson, R N N; Mazinda, C; Kipngetich, S; Ritmeijer, K Citation Publisher
More informationAuthors Abongomera, C; Diro, E; Vogt, F; Tsoumanis, A; Mekonnen, Z; Admassu, H; Colebunders, R; Mohammed, R; Ritmeijer, K; van Griensven, J
MSF Field Research The Risk and Predictors of Visceral Leishmaniasis Relapse in HIV Co-infected Patients in Ethiopia: A Retrospective Cohort Study Authors Abongomera, C; Diro, E; Vogt, F; Tsoumanis, A;
More informationChildren with Visceral Leishmaniasis Presented to Omdurman Emergency Hospital for Children
Original Article Children with Visceral Leishmaniasis Presented to Omdurman Emergency Hospital for Children Elfakey Walyeldinl, Ahmed Muawial, Mohamed Abdurrahman2 and Suwar M 03 Department of Paediatrics
More informationVisceral leishmaniasis: an endemic disease with global impact
Visceral leishmaniasis: an endemic disease with global impact Professor Olivier Lortholary, MD, PhD Department of Infectious and Tropical diseases Hôpital Necker-Enfants Malades Université Paris Descartes
More informationLeishmaniasis, Kala Azar(The Black Fever)
Leishmaniasis, Kala Azar(The Black Fever) By Lawrence Hall Etiologic agent Protist obligate intracellular parasite, Transmission Vectors Phylum: Euglenozoa (genus Leishmania) Over 21 species that infect
More informationA Novel Noninvasive Method for Diagnosis of Visceral Leishmaniasis by. rk39 Test in Sputum Samples
JCM Accepts, published online ahead of print on 0 June 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationFact sheet. Yellow fever
Fact sheet Key facts is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow in the name refers to the jaundice that affects some patients. Up to 50% of severely affected
More informationCountry Focus of study (Objectives) Methods Participants Main findings. Longitudinal follow up study. analysis. study
Table S1: Summary of magnitude of HIV-VL co-infection Author(s) Country Focus of (Objectives) Methods Participants Main findings year of publication Rachel ter Horst et al., 2008 To assess its impact and
More informationPredictors of drug sensitive tuberculosis treatment outcomes among hospitalised
Predictors of drug sensitive tuberculosis treatment outcomes among hospitalised patients in South Africa: a multinomial logit model Abiola O. Olaleye 1,* and Andy K. Beke 1 1 School of Health Systems and
More informationTherapeutic Options for Visceral Leishmaniasis
Drugs (2013) 73:1863 1888 DOI 10.1007/s40265-013-0133-0 REVIEW ARTICLE Therapeutic Options for Visceral Leishmaniasis Begoña Monge-Maillo Rogelio López-Vélez Published online: 30 October 2013 Ó The Author(s)
More informationControl of leishmaniasis
SIXTIETH WORLD HEALTH ASSEMBLY A60/10 Provisional agenda item 12.3 22 March 2007 Control of leishmaniasis Report by the Secretariat BACKGROUND 1. Leishmaniasis is endemic in 88 countries in the world and
More informationCRED Technical Brief: Outbreaks in Fragile States. Yellow Fever in Darfur September December 2012
1th December 212 CRED Technical Brief: Outbreaks in Fragile States. Yellow Fever in Darfur September December 212 This technical brief consists of 2 sections: 1. An Overview of Yellow Fever (p 1-3) 2.
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
8 April 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH PROGRAMME SUBCOMMITTEE Sixty-fourth session Brazzaville, Republic of Congo, 9 11 June 2014 Provisional agenda item 6 VIRAL HEPATITIS: SITUATION
More informationPREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND
JOURNAL OF SCIENCE, Hue University, N 0 61, 2010 PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND Pornnapa
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
5 November 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-fourth session Cotonou, Republic of Benin, 3 7 November 2014 Provisional agenda item 11 VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES
More informationMalaria detection in relation to fever among malnourished children in Ethiopia Have we got it right?
Malaria detection in relation to fever among malnourished children in Ethiopia Have we got it right? M. Khogali., R.Zachariah, A.Keiluhu, K. van den Brande, K. Tayler-Smith, L. Ayada D. Jima, S.G. Hinderaker,
More informationTrends in HIV/AIDS epidemic in Asia, and its challenge. Taro Yamamoto Institute of Tropical Medicine Nagasaki University
Trends in HIV/AIDS epidemic in Asia, and its challenge Taro Yamamoto Institute of Tropical Medicine Nagasaki University Millennium Development Goals Goal 1. Eradicate extreme poverty and hunger Goal 2.
More informationElimination of VL in the Indian subcontinent is it achievable?
Elimination of VL in the Indian subcontinent is it achievable? P Das Rajendra Memorial Research Institute, Patna Jorge Alvar DNDi, Geneva Bhawna Sharma DNDi, India Leishmaniasis 350 million at risk worldwide
More informationTDR/DDR/98.1 WHO, GENEVA, 14 JULY 1998 CONCLUSIONS AND RECOMMENDATIONS RELAPSING PATIENTS. The 14-day regimen is highly effective.
TDR/DDR/98.1 REPORT ON A MEETING OF THE PRODUCT DEVELOPMENT TEAM FOR AFRICAN TRYPANOSOMIASIS CHEMOTHERAPY TO REVIEW THE COMPARATIVE STUDY OF 14-DAY VERSUS 7-DAY TREATMENT OF LATE STAGE T.B. GAMBIENSE AFRICAN
More informationNew insights on leishmaniasis in immunosuppressive conditions
New insights on leishmaniasis in immunosuppressive conditions Javier Moreno Immunoparasitology Unit WHO Collaborative Center for Leishmaniasis Centro Nacional de Microbiología INSTITUTO DE SALUD CARLOS
More informationby author Drug Therapy in African Visceral Leishmaniasis 28th ECCMID Conference, Madrid, Spain 21 April 2018
Drug Therapy in African Visceral Leishmaniasis 28th ECCMID Conference, Madrid, Spain 21 April 2018 Dr. Monique Wasunna, Director, DNDi Africa Regional Office Presentation Outline 1 2 4 5 Introduction leishmaniasis
More informationRESERVOIRS OF INFECTION
CHAPTER 6 TRANSMISSION OF INFECTION, THE COMPROMISED HOST, EPIDEMIOLOGY, AND DIAGNOSING INFECTIONS RESERVOIRS OF INFECTION Transmission is the final requirement for a successful infection Reservoirs are
More informationPharmacokinetics of simultaneously administered antileishmanial and antiretroviral drugs. Ethiopia
Pharmacokinetics of simultaneously administered antileishmanial and antiretroviral drugs in HIV/VL coinfected patients in Ethiopia Anke E. Kip, Séverine Blesson, Fabiana Alves, Robert Kimutai, Peninah
More informationResponse to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.
Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria. Yusuf Mohammed, Mukhtar Dauda, Ifeanyi Oyeyi TB/HIV Unit, International
More informationSummary of Cases & Epidemiology Aspects of Leishmaniasis in Thailand
Summary of Cases & Epidemiology Aspects of Leishmaniasis in Thailand Sukmee T. 1, Mungthin M. 2, Apiwathanasorn C. 3, Leelayoova S. 2 1 Department of Microbiology, Phramongkutklao College of Medicine 2
More informationAddressing climate change driven health challenges in Africa
Addressing climate change driven health challenges in Africa Ednah N Ototo, Parasitologist, Climate Change and Health Kenyatta University, Kenya Kenya Medical Research Institute Outline The impact of climate
More informationMSF Field Research. Concomitant malaria among visceral leishmaniasis inpatients. from Gedarif and Sennar States, Sudan: a retrospective casecontrol
MSF Field Research Concomitant malaria among visceral leishmaniasis in-patients from Gedarif and Sennar States, Sudan: a retrospective casecontrol study Authors Citation van den Bogaart, Erika; Berkhout,
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationYellow fever. Key facts
From: http://www.who.int/en/news-room/fact-sheets/detail/yellow-fever WHO/E. Soteras Jalil Yellow fever 14 March 2018 Key facts Yellow fever is an acute viral haemorrhagic disease transmitted by infected
More informationReport of the. Fifth Consultative Meeting on Leishmania/HIV Coinfection. Addis Ababa, Ethiopia, March 2007
Report of the Fifth Consultative Meeting on Leishmania/HIV Coinfection Addis Ababa, Ethiopia, 20 22 March 2007 WHO/CDS/NTD/IDM/2007.5 Report of the Fifth Consultative Meeting on Leishmania/HIV Coinfection
More informationAIDS was described in June 1981 among homosexuals in the USA, and the virus. HIV/AIDS epidemic features and trends in Saudi Arabia
ORIGINAL ARTICLE HIV/AIDS epidemic features and trends in Saudi Arabia Yagob Y. Al-Mazrou, PhD, FRCGP; Mohamed H. Al-Jeffri, MSc, DTM&H; Abdulla Ibrahim Fidail, DPH, MPH; Nasir Al-Huzaim, MPH, PhD; Sirrag
More informationResearch highlights from a programatic perspective and lessons learnt
Research highlights from a programatic perspective and lessons learnt Findings from operational research on Ebola Engy Ali MD, MPH Operational Research Unit- MSF Luxembourg On behalf of Médecins sans Frontières
More informationBayesian Meta-analysis of Diagnostic Tests
Allowing for Imperfect Reference Standard Institute of Tropical Medicine, L-Biostat KULeuven 10-May-2012 Overview Overview Visceral Leishmaniasis Accuracy of Diagnostic Tests Latent Class Analysis The
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationAuthor Summary. Methods
Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India Sakib Burza 1 *, Prabhat K. Sinha 2, Raman
More informationControl of leishmaniasis
EXECUTIVE BOARD EB118/4 118th Session 11 May 2006 Provisional agenda item 5.1 Control of leishmaniasis Report by the Secretariat BACKGROUND 1. Leishmaniasis is endemic in 88 countries in the world and
More informationDisease Detectives 2016 B/C
Disease Detectives 2016 B/C What you can bring Two (2) non-programmable nongraphing calculators One (1) 8.5 x 11 inch sheet of notes, double sided Difference between B and C division Same types of questions
More informationlovelife is a new lifestyle brand for young South Africans promoting healthy living and positive sexuality. Organised under the auspices of Mrs.
lovelife is a new lifestyle brand for young South Africans promoting healthy living and positive sexuality. Organised under the auspices of Mrs. Zanele Mbeki and other leading South Africans, lovelife
More informationTransactions of the Royal Society of Tropical Medicine and Hygiene
Transactions of the Royal Society of Tropical Medicine and Hygiene 104 (2010) 225 229 Contents lists available at ScienceDirect Transactions of the Royal Society of Tropical Medicine and Hygiene journal
More informationWhat is Kala-azar? What are Signs & Symptoms of Kala-Azar?
What is Kala-azar? Kala-azar is a slow progressing indigenous disease caused by a protozoan parasite of genus Leishmania In India Leishmania donovani is the only parasite causing this disease The parasite
More informationInfertility in Ethiopia: prevalence and associated risk factors
Infertility in Ethiopia: prevalence and associated risk factors Fikrewold Haddis, Ethiopian Public Health Association Daniel Sahleyesus, University of Colorado at Boulder Biruk Tensou, Addis Ababa Mortality
More informationEmergency sanitation: assessment and programme design
Loughborough University Institutional Repository Emergency sanitation: assessment and programme design This item was submitted to Loughborough University's Institutional Repository by the/an author. Citation:
More informationShort-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment
MAJOR ARTICLE Short-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment Shyam Sundar, Neha Agrawal, Rakesh Arora, Dipti Agarwal, Madhukar Rai, and Jaya Chakravarty
More informationEBOLA VIRUS DISEASE. Democratic Republic of Congo. External Situation Report 1. Credit : B.Sensasi / WHO Uganda-2007
EBOLA VIRUS DISEASE Democratic Republic of Congo Credit : B.Sensasi / WHO Uganda-2007 External Situation Report 1 1 Health Emergency Information and Risk Assessment EBOLA VIRUS DISEASE Democratic Republic
More informationOral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial
Tropical Medicine and International Health doi:10.1111/tmi.12015 volume 18 no 1 pp 96 100 january 2013 Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial Shyam Sundar 1,
More informationRisk factors for death in hospitalized dysentery patients in Rwanda
Tropical Medicine and International Health volume 4 no 6 pp 428 432 june 1999 Risk factors for death in hospitalized dysentery patients in Rwanda Dominique Legros 1, Christophe Paquet 1, Fabienne Dorlencourt
More informationFrequently Asked Questions on Visceral Leishmaniasis (Kala-azar)
SEA-CD-274 Frequently Asked Questions on Visceral Leishmaniasis (Kala-azar) World Health Organization 2013 All rights reserved. Requests for publications, or for permission to reproduce or translate WHO
More informationin South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M /j x
MSF Field Research Integrating tuberculosis and HIV care in the primary care setting in South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M Citation DOI Journal Rights
More informationTitle/Description: Outbreak Investigation Guidelines Department: All Departments. Effective Date: 4/97 REVISED: 1/00, 5/08 I.
Title/Description: Outbreak Investigation Guidelines Department: All Departments Personnel: All Personnel Effective Date: 4/97 REVISED: 1/00, 5/08 I. PURPOSE At Springhill Medical Center (SMC) an outbreak
More informationWHO: Forum Issue #02 Student Officer Position:
WHO: Topic B Forum : World Health Organization Issue #02 : Topic B: Preparing for a Global Health Crisis Student Officer : Samantha Portillo Position: Chair of the United Nations World Health Organization
More informationJoseph Njau (K) RN, RM, RPHN, BSc N Cert Applied Epidemiology
Joseph Njau (K) RN, RM, RPHN, BSc N Cert Applied Epidemiology Outline of Presentation Part I Introduction Part II History of Leishmaniasis in Kenya Part III Leishmaniasis Management & Control: Current
More informationCONTROLE DAS LEISHMANIOSES O QUE FALTA FAZER? Centro de Convenções de Reboças Red Room 17: 00h
CONTROLE DAS LEISHMANIOSES O QUE FALTA FAZER? Centro de Convenções de Reboças 08.04.2014 Red Room 17: 00h Leishmaniasis - a Global Problem Visceral 2012 300 000 cases 20,000 deaths (6.7%) 310 million at
More informationCutaneous Leishmaniasis : Global overview
Cutaneous Leishmaniasis : Global overview Meeting of stakeholders for selected Health R&D Demostration Projects, 7-10 May 2014, WHO, Geneva Dr. Daniel Argaw Dagne, NTD/WHO CSR - DDC AFRO Leishmaniasis
More informationWest Nile Virus in the Region of Peel 2002
HUMAN CASE SURVEILLANCE Introduction Human illness caused by mosquito-borne WNV acquired in Peel occurred for the first time in 2002. In 1999, a Peel resident who had traveled to New York City acquired
More informationRift Valley Fever. What is Rift Valley Fever?
Rift Valley Fever What is Rift Valley Fever? Rift Valley fever (RVF) is a peracute or acute insect-borne disease of man and animals, historically restricted to Africa. An outbreak of RVF in animals frequently
More informationNavigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 1. Does my country need JE vaccine?
Navigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 1 Does my country need JE vaccine? 1 about this guide Japanese encephalitis (JE), a viral infection of the
More informationHEALTH ORGANISATIONS. National Health Programme
HEALTH ORGANISATIONS National Health Programme There are various National Health Programmes launched in India to eradicate fatal diseases. National Health Programme launched by Indian government after
More information40% (90% (500 BC)
MALARIA causative agent = Plasmodium species 40% of world s population lives in endemic areas 3-500 million clinical cases per year 1.5-2.7 million deaths (90% Africa) known since antiquity early medical
More informationResearch Article Distribution of Human Leishmaniasis (VL) and Its Associated Risk Factors, in Metemma, Ethiopia
Epidemiology Research International Volume 2015, Article ID 630812, 5 pages http://dx.doi.org/10.1155/2015/630812 Research Article Distribution of Human Leishmaniasis (VL) and Its Associated Risk Factors,
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Isolated in 1983 by Luc Montagnier & Robert Gallo, separately. Genetic material is RNA Carries reverse transcriptase, an enzyme that makes DNA out of RNA in the host cell Cells
More informationRAM U S. D E P A R T M E N T O F H E A L T H. E D U C A T IO N. AND W E LF A R E. J u l y 1970
v u L.u n r. i. v, J u l y 1970 n u n w j y q 6/70 S2.2 J D MILLAR, MO, ACTING 01 RECTOR STATE AND COMMUNITY SERVICES D IV ISIO N BLOG B, ROOM 207 RAM I. C U R R E N T S M A L L P O X M O R B I D I T Y
More informationWhy should AIDS be part of the Africa Development Agenda?
Why should AIDS be part of the Africa Development Agenda? BACKGROUND The HIV burden in Africa remains unacceptably high: While there is 19% reduction in new infections in Sub-Saharan Africa, new infections
More informationEradication of Guinea Worm in Ethiopia. Ayaan Omar. George Mason University. GCH Health and Environment, Fall 2014, Due: December 3, 2014
Eradication of Guinea Worm in Ethiopia 1 Eradication of Guinea Worm in Ethiopia Ayaan Omar George Mason University GCH 360-002 - Health and Environment, Fall 2014, Due: December 3, 2014 Introduction Eradication
More informationCerebral malaria in children
Cerebral malaria in children M. Chiara Stefanini Catholic University - Rome Malaria: epidemiology Global distribution of malaria transmission risk,, 2003 World malaria report, WHO, 2005 Estimated incidence
More informationEBOLA VIRUS DISEASE. Democratic Republic of Congo. External Situation Report 2 Date of issue: 16 May Situation update
EBOLA VIRUS DISEASE Democratic Republic of Congo External Situation Report 2 Date of issue: 16 May 2017 1. Situation update WHO continues to monitor the outbreak of Ebola virus disease (EVD) in Likati
More informationDeveloping diagnostic guidance for persistent fever:
Developing diagnostic guidance for persistent fever: the NIDIAG study François Chappuis Geneva University Hospitals on behalf of NIDIAG partners What is NIDIAG? Objective: improve diagnostic approaches
More informationAOHS Global Health. Unit 1, Lesson 3. Communicable Disease
AOHS Global Health Unit 1, Lesson 3 Communicable Disease Copyright 2012 2016 NAF. All rights reserved. A communicable disease is passed from one infected person to another The range of communicable diseases
More informationCase Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive)
Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) July 2012 May 2018 December 2005 Case Definition Confirmed Case Clinical
More informationQ&A on HIV/AIDS estimates
Q&A on HIV/AIDS estimates 07 Last updated: November 2007 Understanding the latest estimates of the 2007 AIDS Epidemic Update Part one: The data 1. What data do UNAIDS and WHO base their HIV prevalence
More informationMERS H7N9. coronavirus. influenza virus. MERS: Since September 2012: 160 cases, including 68 deaths (42%)
MERS coronavirus H7N9 influenza virus Marc Van Ranst, KU Leuven MERS: Since September 2012: 160 cases, including 68 deaths (42%) MERS coronavirus patient, 83 years, Saudi-Arabia H7N9: Since February 2013:
More informationMarburg virus disease
Marburg virus disease Fact sheet available at http://www.who.int/mediacentre/factsheets/fs_marburg/en/ Updated 20 October 2017 Key facts Marburg virus disease (MVD), formerly known as Marburg haemorrhagic
More informationDr. Charles Tobin-West Department of Preventive and Social Medicine College of Health Sciences University of Port Harcourt
Dr. Charles Tobin-West Department of Preventive and Social Medicine College of Health Sciences University of Port Harcourt Sexual risk behaviors are among the key drivers of the HIV epidemic in Nigeria,
More informationModule 1: HIV epidemiology, transmission and prevention
Session 1 Module goals Module 1 Participants will be able to: -offer an insight into the epidemiological situation in the country and worldwide -present the HIV transmission modes and the broad approaches
More informationUNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,
U N A I D S B E S T P R A C T I C E C O L L E C T I O N Drug use and HIV/AIDS UNAIDS statement presented at the United Nations General Assembly Special Session on Drugs Joint United Nations Programme on
More informationClinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation
ISPUB.COM The Internet Journal of Infectious Diseases Volume 6 Number 2 Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation Y Graza,
More informationCOHORT STUDY OF HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS in PENANG HOSPITAL: COMPARISON OF CLINICAL MANIFESTATIONS
COHORT STUDY OF HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS in PENANG HOSPITAL: COMPARISON OF CLINICAL MANIFESTATIONS Ong CK 1, Tan WC 2, Leong KN 2, Abdul Razak M 1, Chow TS 2 1 Respiratory Unit, Penang
More informationMALARIA INFECTION AMONG THE MIGRANT POPULATION ALONG THE THAI-MYANMAR BORDER AREA
MALARIA INFECTION AMONG THE MIGRANT POPULATION ALONG THE THAI-MYANMAR BORDER AREA Wisit Chaveepojnkamjorn and Natchaporn Pichainarong Department of Epidemiology, Faculty of Public Health, Mahidol University,
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationDr Monique Wasunna MBChB, PhD, DTM&H DNDi Africa Regional office. WorldLeish6 Congress, Toledo Spain
Phase II Randomized Clinical Trial of the Efficacy and Safety of AmBisome in Combination with SSG or Miltefosine versus Miltefosine Monotherapy for African VL Dr Monique Wasunna MBChB, PhD, DTM&H DNDi
More informationResearch articles.
Research articles Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom M Strong (m.strong@sheffield.ac.uk)
More informationNotes Setting the Scene
We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles in diagnosing patients but also after diagnosis, helping
More informationEfficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
MAJOR ARTICLE Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use Shyam Sundar, 1,a Anup Singh, 1,a Madhukar Rai, 1 Vijay K. Prajapati, 1 Avinash K. Singh,
More informationMidland infectious disease activity summary (MIDAS), Vol 1 (9), Oct 09
Midland infectious disease activity summary (MIDAS), Vol 1 (9), Oct 09 Item Type Other Authors Health Service Executive (HSE) Dublin/Mid-Leinster (Midlands), Publisher Health Service Executive (HSE) Dublin/Mid-Leinster
More informationIntensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite
Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.
More informationSingle-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study
MAJOR ARTICLE Single-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study S. Sundar, 1 T. K. Jha, 2 C. P. Thakur, 3 M. Mishra, 4 V. P. Singh, 1 and R.
More informationAuthor Manuscript Faculty of Biology and Medicine Publication
Serveur Académique Lausannois SERVAL serval.unil.ch Author Manuscript Faculty of Biology and Medicine Publication This paper has been peer-reviewed but dos not include the final publisher proof-corrections
More informationImproving HIV management in Sub-Saharan Africa: how much palliative care is needed?
Improving HIV management in Sub-Saharan Africa: how much palliative care is needed? Karilyn Collins, Richard Harding To cite this version: Karilyn Collins, Richard Harding. Improving HIV management in
More informationUnwell returned traveller
Unwell returned traveller Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date):
More informationAnnual Epidemiological Report
November 2018 Annual Epidemiological Report 1 HIV in Ireland, 2017 Key Facts There were 492 diagnoses of HIV notified in 2017, a rate of 10.3 per 100,000 population. The HIV rate in Ireland has been relatively
More informationChapter 2 Epidemiology. Multiple Choice Questions
Medical Sociology 13th Edition Cockerham TEST BANK Full download at: https://testbankreal.com/download/medical-sociology-13th-editioncockerham-test-bank/ Medical Sociology 13th Edition Cockerham SOLUTIONS
More information2004 Update. Luxembourg
2004 Update Luxembourg 2 Luxembourg HIV/AIDS estimates In 2003 and during the first quarter of 2004, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current
More informationMid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006
Mid-term Review of the UNGASS Declaration of Commitment on HIV/AIDS Ireland 2006 Irish Role in Global Response Just as the HIV/AIDS epidemic is a global threat, addressing the challenge of the epidemic
More informationMedia centre Global infectious disease surveillance
Media centre Global infectious disease surveillance Fact sheet N 200 Increased movements of people, expansion of international trade in foodstuffs and medicinal biological products, social and environmental
More information